Fig. 4
In vivo experiments of NSG mice bearing GD2 + sarcoma cells (RD, 143B or U-2OS) treated with NT or CAR.GD2 T-cells. Experimental design (Figure created using Biorender—https://biorender.com) and in vivo bioluminescence imaging time-course of RD-GFP-FF-Luc tumor cells (A), 143B-GFP-FF-Luc (F) and U-2OS-GFP-FF-Luc (K) infused in NSG mice. At the time of tumor engraftment, 106 effector T-cells were administered through i.v. injection. The graph shows bioluminescence analysis of RD (ERMS) (B, C), 143B (OS) (G, H) and U-2OS (OS) (L, M) tumor-bearing mice model treated with NT T-cells (square symbol) or CAR.GD2 T-cells (dot symbol). Overall-Survival (OS) of RD (ERMS) (D) and 143B (OS) (I) tumor-bearing NSG mice treated with NT T-cells (black line) or CAR.GD2 T-cells (blue and red respectively). Two-way ANOVA was applied for the analysis. *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001 and **** ≤ 0.0001. (N) Explanted tumor-volume mass on sacrifice for NT T-cells and GD2.CAR T-cells mice group in U-2OS (OS) tumor model. Two-way ANOVA was applied for the analysis. *p-value ≤ 0.05; **p-value ≤ 0.01; *** p-value ≤ 0.001 and **** ≤ 0.0001. Average of circulating human T-cells evaluated as % of CD45 + CD3 + (NT T-cells, square symbol) and CD3 + CAR + (CAR.GD2 T-cells dot symbol) until NSG-tumor bearing sacrifice for RD (ERMS) (E), 143B (OS) (J) and U2-OS (O) model. T-test and Two-way ANOVA was applied for the analysis. *p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001 and **** ≤ 0.0001